Brazil and Paraguay Sign Agreement to Raise Standards of Health Surveillance in Latin America
The cooperation between Brazil and Paraguay to combat irregular medicines through enhanced health surveillance.
ANVISA | Pharmaceuticals | Regulatory AffairsANVISA's Board of Directors Expands List of Radiopharmaceutical Drugs
ANVISA's Board of Directors discussed and approved updates on regulations for radiopharmaceutical drugs during their 5th Public Meeting of 2026.
ANVISA | Pharmaceuticals | Regulatory AffairsGGMON Communication 003/2021: Notification of Adverse Drug Events
The regulation and monitoring of adverse drug events related to medications and the importance of reporting these events to ensure public health safety.
ANVISA | Pharmaceuticals | Regulatory AffairsANVISA Normative Instruction No. 433, of April 1, 2026: Approves the Lists of Radiopharmaceuticals for Therapeutic and Diagnostic Use That May Present Literature Data to Demonstrate Safety and Efficacy
Approves official lists of radiopharmaceuticals permitted for diagnostic and therapeutic use in Brazil, allowing the use of published clinical literature to demonstrate safety and efficacy for regulatory purposes.
ANVISA | Pharmaceuticals | Regulatory AffairsGuide to CTD Registration & Modification for Medicinal Products and Biologics (Annexes)
Overview of requirements and formats for the application, modification, and documentation of the sanitary registration of medicines and biological products in Mexico.
COFEPRIS | Pharmaceuticals | Regulatory Affairs
Consult
